NCT06626230RecruitingPhase 1
Safety of Anal Curcumin
An Incremental Dose Escalation Trial of Safety and Tolerability of Curcumin
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 1 Oct 2024
- Start date
- 17 Mar 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Lisa Flowers
- NCT number
- NCT06626230
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 48
- From 17 Mar 2025 to the primary completion date, Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Are currently using, or in the last year have used intravenous drugs (except for therapeutic use), recreational drugs, or alcohol abuse.
Other illness
- Have a clinically significant chronic medical condition that is considered progressive, such as but not limited to coronary disease, congestive heart failure, chronic obstructive lung disease, and diabetes mellitus. Chronic nonprogressive or intermittent syndromes are not excluded, including migraine headaches, mild reactive airway disease, controlled hypertension, stable pain syndromes, or benign gastric reflux.
- Have any history of anal cancer malignancy.
- Have a history of sensitivity or allergy to any compound used in this study.
Other
- Pregnant or planning to become pregnant in the next three months.
- Have Grade 2 or higher renal or hematology abnormality,
- Other exclusion criteria apply
Criteria the registry did not label
- Major Inclusion Criteria:
- 30 and older
- Have biopsy-proven anal intraepithelial neoplasia (AIN) 2, AIN 3 without previous treatment
- Or cytology results for ASC-H or HSIL
- Able and willing to complete Study Diary
- Other inclusion criteria apply
Age in the registry: 30 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Grady Memorial Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| Grady Hospital - Ponce De Leon Clinic Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.